secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001104659-24-114101
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025
---------------------------------------------------------------------

- FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.
- FDA requested final datasets and clinical study report from long-term extension study, deemed a major amendment.
- No concerns raised regarding safety, efficacy, or approvability of VTAMA for atopic dermatitis.
- Organon expects VTAMA full-year 2025 revenue of ~$125M; impact of ~75 bps headwind to Adjusted EBITDA margin.
- Updated guidance provided as a supplement to prior Q3 2024 earnings call commentary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924114101/0001104659-24-114101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924114101/tm2427489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer